Risk Factors for Febrile Neutropenia in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Undergoing Initial R-CHOP Treatment.
Background: Febrile neutropenia (FN) frequently occurs as a complication among patients with diffuse large B-cell lymphoma (DLBCL) receiving their initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. This study aimed to identify the risk factors for FN...
| Publicado en: | Clinical Medicine Insights: Oncology Vol. 20; pp. 1 - 9 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
2/18/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |